MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-21-2026
Immutep Limited Total Liabilities 2011-2026 | IMMP
Annual Total Liabilities Immutep Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.3 M | 12.1 M | 11 M | 8.09 M | 8.76 M | 13.3 M | 16.2 M | 13.5 M | 8.43 M | 7.24 M | 6.29 M | 2.79 M | 3.57 M | 4.45 M | 2.54 M |
All numbers in AUD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.2 M | 2.54 M | 8.76 M |
Quarterly Total Liabilities Immutep Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 8.76 M | - | - | - | 13.3 M | - | - | - | 16.2 M | - | - | - | 13.5 M | - | - | - | 8.43 M | - | - | - | 7.24 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in AUD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16.2 M | 7.24 M | 11.2 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.33 | 0.91 % | $ 8.01 B |  Australia |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M |  USA |
 |
Aurinia Pharmaceuticals
AUPH
|
170 M | $ 14.11 | -3.13 % | $ 1.9 B |  Canada |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M | Canada |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B |  France |
 |
Aileron Therapeutics
ALRN
|
7.8 M | - | 10.36 % | $ 9.8 M | USA |
 |
BioVie
BIVI
|
2.55 M | $ 1.29 | -3.31 % | $ 1.91 M | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
1.47 B | $ 216.01 | -0.94 % | $ 5 B |  Danmark |
 |
BioNTech SE
BNTX
|
2.76 B | $ 86.86 | -1.75 % | $ 27.2 B | Germany |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
840 M | $ 19.42 | 0.99 % | $ 908 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
20.7 M | $ 8.18 | -3.02 % | $ 109 M | USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | Canada |
 |
CytomX Therapeutics
CTMX
|
52.6 M | $ 4.2 | -5.83 % | $ 579 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
5.24 M | $ 0.73 | 20.26 % | $ 8.36 M |  Israel |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Eton Pharmaceuticals
ETON
|
66 M | $ 22.9 | -3.82 % | $ 616 M | USA |
 |
Exelixis
EXEL
|
683 M | $ 41.46 | 0.12 % | $ 11.3 B | USA |
 |
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
355 M | $ 1.35 | -3.34 % | $ 344 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | Israel |
 |
ChemoCentryx
CCXI
|
140 M | - | - | $ 3.74 B | USA |
 |
Aytu BioScience
AYTU
|
93.3 M | $ 2.6 | -1.14 % | $ 16.3 M | USA |
 |
Fulcrum Therapeutics
FULC
|
17.3 M | $ 6.64 | -3.63 % | $ 421 K | USA |
 |
Atreca
BCEL
|
76.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
137 M | - | -4.8 % | $ 255 M | USA |
 |
Genmab A/S
GMAB
|
2.02 B | $ 25.62 | -0.23 % | $ 16.4 B | Danmark |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Grifols, S.A.
GRFS
|
12.8 B | $ 7.6 | -1.24 % | $ 6.83 B |  Spain |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
BeiGene, Ltd.
BGNE
|
3.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Halozyme Therapeutics
HALO
|
2.48 B | $ 61.92 | -1.5 % | $ 7.42 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | USA |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
18 M | $ 4.29 | -2.94 % | $ 822 M | Canada |
 |
Incyte Corporation
INCY
|
1.79 B | $ 90.93 | 0.53 % | $ 17.7 B | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |